Suppr超能文献

体内光免疫治疗期间抗体 - 光子吸收剂偶联物微分布的实时监测。

Real-time monitoring of microdistribution of antibody-photon absorber conjugates during photoimmunotherapy in vivo.

作者信息

Tang Qinggong, Nagaya Tadanobu, Liu Yi, Lin Jonathan, Sato Kazuhide, Kobayashi Hisataka, Chen Yu

机构信息

University of Maryland, Fischell Department of Bioengineering, 2218 Jeong H.Kim Engineering Building, College Park, MD 20742, United States.

National Institute of Health, National Cancer Institute, Molecular Imaging Program, Bldg 10, Room B3B69, Bethesda, MD 20892-1088, United States.

出版信息

J Control Release. 2017 Aug 28;260:154-163. doi: 10.1016/j.jconrel.2017.06.004. Epub 2017 Jun 8.

Abstract

Photoimmunotherapy (PIT) is an emerging low side effect cancer therapy based on a monoclonal antibody (mAb) conjugated with a near-infrared (NIR) phthalocyanine dye IRDye 700DX. IR700 is fluorescent, can be used as an imaging agent, and also is phototoxic. It induces rapid cell death after exposure to NIR light. PIT induces highly selective cancer cell death, while leaving most of tumor blood vessels unharmed, leading to an effect called super-enhanced permeability and retention (SUPR). SUPR significantly improves the effectiveness of the anticancer drug. Currently, the therapeutic effects of PIT are monitored using the IR700 fluorescent signal based on macroscopic fluorescence reflectance imagery. This technique, however, lacks the resolution and depth information to reveal the intratumor heterogeneity of mAb-IR700 distribution. We applied a minimally invasive two-channel fluorescence fiber imaging system by combining the traditional fluorescence imaging microscope with two imaging fiber bundles (~0.85mm). This method monitored mAb-IR700 distribution and therapeutic effects during PIT at different intratumor locations (e.g., tumor surface vs. deep tumor) in situ and in real time simultaneously. This enabled evaluation of the therapeutic effects in vivo and treatment regimens. The average IR700 fluorescence intensity recovery after PIT to the tumor surface is 91.50%, while it is 100.63% in deep tumors. To verify the results, two-photon microscopy combined with a microprism was also used to record the mAb-IR700 distribution and fluorescence intensity of green fluorescent protein (GFP) at different tumor depths during PIT. After PIT treatment, there was significantly higher IR700 fluorescence recovery in deep tumor than in the tumor surface. This phenomenon can be explained by increased vascular permeability immediately after NIR-PIT. Fluorescence intensity of GFP at the tumor surface decreased significantly more compared to that of deep tumor and in controls (no PIT).

摘要

光免疫疗法(PIT)是一种新兴的低副作用癌症治疗方法,它基于一种与近红外(NIR)酞菁染料IRDye 700DX偶联的单克隆抗体(mAb)。IR700具有荧光性,可作为成像剂,同时也具有光毒性。在暴露于近红外光后,它会诱导细胞迅速死亡。PIT能诱导高度选择性的癌细胞死亡,同时使大多数肿瘤血管不受损伤,从而产生一种称为超增强渗透与滞留(SUPR)的效应。SUPR能显著提高抗癌药物的疗效。目前,基于宏观荧光反射成像,利用IR700荧光信号来监测PIT的治疗效果。然而,该技术缺乏分辨率和深度信息,无法揭示mAb-IR700在肿瘤内部分布的异质性。我们通过将传统荧光成像显微镜与两个成像纤维束(约0.85毫米)相结合,应用了一种微创双通道荧光纤维成像系统。该方法能在原位实时同时监测PIT过程中不同肿瘤内部位置(如肿瘤表面与肿瘤深部)的mAb-IR700分布和治疗效果。这使得能够在体内评估治疗效果和治疗方案。PIT后肿瘤表面的IR700荧光强度平均恢复率为91.50%,而深部肿瘤为100.63%。为了验证结果,还使用了双光子显微镜结合微棱镜来记录PIT过程中不同肿瘤深度处mAb-IR700的分布以及绿色荧光蛋白(GFP)的荧光强度。PIT治疗后,深部肿瘤的IR700荧光恢复明显高于肿瘤表面。这种现象可以通过近红外光免疫治疗后血管通透性立即增加来解释。与深部肿瘤和对照组(未进行PIT)相比,肿瘤表面GFP的荧光强度下降更为显著。

相似文献

引用本文的文献

4
Use of photoimmunoconjugates to characterize ABCB1 in cancer cells.使用光免疫偶联物来表征癌细胞中的ABCB1。
Nanophotonics. 2021 Sep;10(12):3049-3061. doi: 10.1515/nanoph-2021-0252. Epub 2021 Jul 26.
8
Near-Infrared Photoimmunotherapy of Cancer.近红外光免疫治疗癌症。
Acc Chem Res. 2019 Aug 20;52(8):2332-2339. doi: 10.1021/acs.accounts.9b00273. Epub 2019 Jul 23.

本文引用的文献

3
Near infrared photoimmunotherapy of B-cell lymphoma.近红外光免疫治疗 B 细胞淋巴瘤。
Mol Oncol. 2016 Nov;10(9):1404-1414. doi: 10.1016/j.molonc.2016.07.010. Epub 2016 Jul 29.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验